Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2004 Dec 20;14(24):6017-21.

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.

Author information

1
Department of Bioorganic Chemistry, CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304, USA.

Abstract

New inhibitors of palmitoyl-CoA oxidation are based on the introduction of nitrogen heterocycles in the 'Western Portion' of the molecule. SAR studies led to the discovery of CVT-4325 (shown), a potent FOXi (IC50=380 nM rat mitochondria) with favorable PK properties (F=93%, t(1/2)=13.6h, dog).

PMID:
15546720
DOI:
10.1016/j.bmcl.2004.09.077
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center